Allena Pharmaceuticals, Inc.
ALNA · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $8 | -$7 | $9 |
| G&A Expenses | $3 | $4 | $1 | $3 |
| SG&A Expenses | $3 | $4 | $1 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $12 | -$6 | $12 |
| Operating Income | -$8 | -$12 | $5 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$8 | -$12 | $5 | -$13 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$9 | -$12 | $6 | -$13 |
| % Margin | – | – | – | – |
| EPS | -0.085 | -0.13 | 0.074 | -0.17 |
| % Growth | 34.6% | -275.4% | 143.6% | – |
| EPS Diluted | -0.085 | -0.13 | 0.074 | -0.17 |
| Weighted Avg Shares Out | 101 | 89 | 77 | 77 |
| Weighted Avg Shares Out Dil | 101 | 89 | 77 | 77 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$11 | $5 | -$12 |
| % Margin | – | – | – | – |